SG/CALL/ROCHE GS/400/0.1/21.06.24 Stock

Warrant

DE000SN2L7B7

Market Closed - Deutsche Boerse AG 15:45:00 2024-05-10 EDT
0.001 EUR 0.00% Intraday chart for SG/CALL/ROCHE GS/400/0.1/21.06.24
Current year-98.63%
Date Price Change Volume
24-05-10 0.001 0.00% 0
24-05-09 0.001 0.00% 0
24-05-08 0.001 0.00% 0
24-05-07 0.001 0.00% 0
24-05-06 0.001 0.00% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 03:45 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Société Générale Société Générale
WKN SN2L7B
ISINDE000SN2L7B7
Date issued 2022-05-27
Strike 400 CHF
Maturity 2024-06-21 (42 Days)
Parity 10 : 1
Emission price 1.41
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.39
Lowest since issue 0.001
Spread 0.074
Spread %98.67%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+24.12%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW